Physician profile
Maxine Mitchell
NPI 1104970441
$2,548.41
in general payments reported to CMS, 2019-2025
23 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $416 · 2023: $680 · 2024: $703 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $659.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.13 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $232.67 | 2021-2025 | |
| Abbvie INC. | $213.97 | 2021-2025 | |
| Novo Nordisk INC | $202.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $178.38 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $175.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $165.24 | 2022-2025 | |
| Shield Therapeutics INC | $68.77 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.50 | 2022 | |
| Merck Sharp & Dohme LLC | $37.46 | 2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.77 | 2024 | Xifaxan |
| Boston Scientific Corporation | $24.84 | 2024 | |
| Mylan Specialty L.P. | $24.03 | 2023 | Yupelri |
| Astellas Pharma US INC | $23.57 | 2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.40 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.33 | 2024 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $18.94 | 2022 | |
| Hologic Sales and Service, LLC | $18.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.86 | 2024 | Voquezna |
| Abbott Laboratories | $14.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.66 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxine Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.